(a) contacting said sample having said neutralizing agent and a competing drug to said therapeutic protein, a target of said therapeutic protein, and a mitigating agent;

(b) measuring a binding of said therapeutic protein to said target; and

(c) comparing the result of (b) to a control measurement to detect said neutralizing agent.

2. The method of claim **1**, wherein said control measurement includes measuring binding of said therapeutic protein to said target in the absence of a neutralizing agent.

3. The method of claim **1**, wherein said neutralizing agent is a neutralizing antibody.

4. The method of claim **1**, wherein said therapeutic protein is selected from a group consisting of an antibody, a soluble receptor, an antibody-drug conjugate, and an enzyme.

5. The method of claim **1**, wherein said therapeutic protein is a monoclonal antibody.

6. The method of claim **5**, wherein said monoclonal antibody is selected from a group consisting of an anti-PD-1 antibody, an anti-TNF antibody, an anti-PD-L1 antibody, an anti-EGFR antibody, an anti-CD20 antibody, an anti-CD38 antibody, and an anti-LAG3 antibody.

7. The method of claim **1**, wherein said therapeutic protein is a bispecific antibody.

8. The method of claim **7**, wherein said bispecific antibody is selected from a group consisting of a CD20×CD3 antibody, a BCMA×CD3 antibody, a EGFR×CD28 antibody, and a CD38×CD28 antibody.

9. The method of claim **1**, wherein said therapeutic protein is immobilized to a solid support.

10. The method of claim **1**, wherein said therapeutic protein is labeled for detection.

11. The method of claim **10**, wherein said label is detectable by fluorescence, chemiluminescence, electrochemiluminescence, radioactivity, or affinity purification.

12. The method of claim **11**, where said label comprises ruthenium.

13. The method of claim **1**, wherein said target is an antigen, a receptor, a ligand, or an enzymatic substrate.

14. The method of claim **1**, wherein said target is a cell surface protein.

15. The method of claim **1**, wherein said target is a recombinant protein.

16. The method of claim **1**, wherein said target is expressed by a cell.

17. The method of claim **16**, wherein said cell is a HEK293 cell, a MOLP-8 cell, a Jurkat cell, or a modified version thereof.

18. The method of claim **1**, wherein said target is immobilized to a solid support.

19. The method of claim **1**, wherein said target is labeled for detection.

20. The method of claim **19**, wherein said label is detectable by fluorescence, chemiluminescence, electrochemiluminescence, radioactivity, or affinity purification.

21. The method of claim **1**, wherein said target is an enzymatic substrate.

22. The method of claim **1**, wherein said target is CD20, CD3, BCMA, PD-1, EGFR, CD28, CD38, TNF, PD-L1, or LAG3.

23. The method of claim **1**, additionally comprising a second target.

24. The method of claim **1**, wherein said competing drug is a monoclonal antibody.

25. The method of claim **24**, wherein said competing drug is rituximab, pembrolizumab, nivolumab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, ublituximab, cetuximab, daratumumab, or adalimumab.

26. The method of claim **1**, wherein said competing drug is a bispecific antibody.

27. The method of claim **1**, wherein said mitigating agent is a monoclonal antibody.

28. The method of claim **1**, comprising using two, three, four or more mitigating agents.

29. The method of claim **1**, wherein a binding of said therapeutic protein to said target is measured by measuring receptor phosphorylation, phosphorylation of downstream proteins in a signal transduction pathway, cytokine release, cell proliferation, cell death, or production of a secondary protein.

30. The method of claim **1**, wherein a binding of said therapeutic protein to said target is measured by the expression of a reporter gene.

31. The method of claim **30**, wherein said reporter gene is luciferase.

32. The method of claim **1**, further comprising a pretreatment step of contacting said sample to said mitigating agent prior to contacting said sample to said therapeutic protein or said target.

33. A kit, comprising:

(a) a therapeutic protein;

(b) a target of said therapeutic protein;

(c) a neutralizing agent against said therapeutic protein;

(d) a competing drug; and

(e) a mitigating agent.

34. The kit of claim **33**, further comprising cells that express said target.

35. The kit of claim **34**, further comprising cells that produce a measurable activity or signal in response to the binding of said therapeutic protein to said target.

36. The kit of claim **35**, wherein said activity is the expression of luciferase.

37. The kit of claim **33**, wherein said target is immobilized to a solid support.

38. The kit of claim **33**, further comprising a label affixed to said therapeutic protein.

39. The kit of claim **38**, wherein said label comprises ruthenium.

* * * * *